411 related articles for article (PubMed ID: 16874782)
1. Scleroderma lung: initial forced vital capacity as predictor of pulmonary function decline.
Plastiras SC; Karadimitrakis SP; Ziakas PD; Vlachoyiannopoulos PG; Moutsopoulos HM; Tzelepis GE
Arthritis Rheum; 2006 Aug; 55(4):598-602. PubMed ID: 16874782
[TBL] [Abstract][Full Text] [Related]
2. Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study.
Khanna D; Clements PJ; Furst DE; Chon Y; Elashoff R; Roth MD; Sterz MG; Chung J; FitzGerald JD; Seibold JR; Varga J; Theodore A; Wigley FM; Silver RM; Steen VD; Mayes MD; Connolly MK; Fessler BJ; Rothfield NF; Mubarak K; Molitor J; Tashkin DP;
Arthritis Rheum; 2005 Feb; 52(2):592-600. PubMed ID: 15692967
[TBL] [Abstract][Full Text] [Related]
3. A prospective study of pulmonary function in patients treated with paclitaxel and carboplatin.
Dimopoulou I; Galani H; Dafni U; Samakovii A; Roussos C; Dimopoulos MA
Cancer; 2002 Jan; 94(2):452-8. PubMed ID: 11900231
[TBL] [Abstract][Full Text] [Related]
4. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma.
Hoyles RK; Ellis RW; Wellsbury J; Lees B; Newlands P; Goh NS; Roberts C; Desai S; Herrick AL; McHugh NJ; Foley NM; Pearson SB; Emery P; Veale DJ; Denton CP; Wells AU; Black CM; du Bois RM
Arthritis Rheum; 2006 Dec; 54(12):3962-70. PubMed ID: 17133610
[TBL] [Abstract][Full Text] [Related]
5. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement.
Steen V; Medsger TA
Arthritis Rheum; 2003 Feb; 48(2):516-22. PubMed ID: 12571862
[TBL] [Abstract][Full Text] [Related]
6. The presence of anti-centromere antibodies may predict progression of estimated pulmonary arterial systolic pressure in systemic sclerosis.
Kampolis C; Plastiras S; Vlachoyiannopoulos P; Moyssakis I; Tzelepis G
Scand J Rheumatol; 2008; 37(4):278-83. PubMed ID: 18612928
[TBL] [Abstract][Full Text] [Related]
7. Determinants of pulmonary arterial hypertension in scleroderma.
Plastiras SC; Karadimitrakis SP; Kampolis C; Moutsopoulos HM; Tzelepis GE
Semin Arthritis Rheum; 2007 Jun; 36(6):392-6. PubMed ID: 17204309
[TBL] [Abstract][Full Text] [Related]
8. Cyclophosphamide versus placebo in scleroderma lung disease.
Tashkin DP; Elashoff R; Clements PJ; Goldin J; Roth MD; Furst DE; Arriola E; Silver R; Strange C; Bolster M; Seibold JR; Riley DJ; Hsu VM; Varga J; Schraufnagel DE; Theodore A; Simms R; Wise R; Wigley F; White B; Steen V; Read C; Mayes M; Parsley E; Mubarak K; Connolly MK; Golden J; Olman M; Fessler B; Rothfield N; Metersky M;
N Engl J Med; 2006 Jun; 354(25):2655-66. PubMed ID: 16790698
[TBL] [Abstract][Full Text] [Related]
9. [Changes in pulmonary function in SARS patients during the three-year convalescent period].
Liu YX; Ye YP; Zhang P; Chen J; Ye H; He YH; Li N
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2007 Sep; 19(9):536-8. PubMed ID: 17767822
[TBL] [Abstract][Full Text] [Related]
10. Does lobectomy for lung cancer in patients with chronic obstructive pulmonary disease affect lung function? A multicenter national study.
Baldi S; Ruffini E; Harari S; Roviaro GC; Nosotti M; Bellaviti N; Venuta F; Diso D; Rea F; Schiraldi C; Durigato A; Pavanello M; Carretta A; Zannini P
J Thorac Cardiovasc Surg; 2005 Dec; 130(6):1616-22. PubMed ID: 16308007
[TBL] [Abstract][Full Text] [Related]
11. Persistence of abnormal bronchoalveolar lavage findings after cyclophosphamide treatment in scleroderma patients with interstitial lung disease.
Mittoo S; Wigley FM; Wise R; Xiao H; Hummers L
Arthritis Rheum; 2007 Dec; 56(12):4195-202. PubMed ID: 18050251
[TBL] [Abstract][Full Text] [Related]
12. Pulmonary function in children treated for rhabdomyosarcoma.
Kaplan E; Sklar C; Wilmott R; Michaels S; Ghavimi F
Med Pediatr Oncol; 1996 Aug; 27(2):79-84. PubMed ID: 8649324
[TBL] [Abstract][Full Text] [Related]
13. Clinical correlations and pulmonary function at 8 years of age after severe neonatal respiratory failure.
Majaesic CM; Jones R; Dinu IA; Montgomery MD; Sauve RS; Robertson CM
Pediatr Pulmonol; 2007 Sep; 42(9):829-37. PubMed ID: 17654569
[TBL] [Abstract][Full Text] [Related]
14. Reduced exercise capacity in systemic sclerosis patients without pulmonary involvement.
de Oliveira NC; dos Santos Sabbag LM; Ueno LM; de Souza RB; Borges CL; de Sá Pinto AL; Lima FR
Scand J Rheumatol; 2007; 36(6):458-61. PubMed ID: 18092268
[TBL] [Abstract][Full Text] [Related]
15. Pulmonary arterial hypertension and severe pulmonary fibrosis in systemic sclerosis patients with a nucleolar antibody.
Steen VD; Lucas M; Fertig N; Medsger TA
J Rheumatol; 2007 Nov; 34(11):2230-5. PubMed ID: 17937469
[TBL] [Abstract][Full Text] [Related]
16. Respiratory systems abnormalities and clinical milestones for patients with amyotrophic lateral sclerosis with emphasis upon survival.
Vender RL; Mauger D; Walsh S; Alam S; Simmons Z
Amyotroph Lateral Scler; 2007 Feb; 8(1):36-41. PubMed ID: 17364434
[TBL] [Abstract][Full Text] [Related]
17. Using quantitative CT to predict postoperative pulmonary function in patients with lung cancer.
Liu F; Han P; Feng GS; Liang B; Xiao J; Tian ZL; Lei ZQ
Chin Med J (Engl); 2005 May; 118(9):742-6. PubMed ID: 15899136
[TBL] [Abstract][Full Text] [Related]
18. Changes in forced vital capacity over time in systemic sclerosis: application of group-based trajectory modelling.
Man A; Davidyock T; Ferguson LT; Ieong M; Zhang Y; Simms RW
Rheumatology (Oxford); 2015 Aug; 54(8):1464-71. PubMed ID: 25784774
[TBL] [Abstract][Full Text] [Related]
19. Association of C-reactive protein with high disease activity in systemic sclerosis: results from the Canadian Scleroderma Research Group.
Muangchan C; Harding S; Khimdas S; Bonner A; ; Baron M; Pope J
Arthritis Care Res (Hoboken); 2012 Sep; 64(9):1405-14. PubMed ID: 22556030
[TBL] [Abstract][Full Text] [Related]
20. Coexistent emphysema delays the decrease of vital capacity in idiopathic pulmonary fibrosis.
Akagi T; Matsumoto T; Harada T; Tanaka M; Kuraki T; Fujita M; Watanabe K
Respir Med; 2009 Aug; 103(8):1209-15. PubMed ID: 19251407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
